Revolution Medicines has announced a notable increase in survival rates for pancreatic cancer treatment, with overall survival rising from 13.2 months to 6.7 months.
The focus on lung cancer drug advancements continues as researchers explore new therapeutic options.
Additionally, there is a growing emphasis on the expansion of the biotech sector in China, which is becoming increasingly significant in the global market.